Blog
RSS FeedPosted by Michael Wonder on 13 Nov 2023
SMC - November 2023 decisions
13 November 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 10 Nov 2023
Public Summary Documents – July 2023 PBAC meeting (round 2)
10 November 2023 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2023 ...
Posted by Michael Wonder on 09 Nov 2023
What next for PHARMAC boss after 'sick, sneering' remarks about Rachel Smalley?
10 November 2023 - PHARMAC’s CEO has managed to survive scrutiny from her board over sneering remarks made about broadcaster ...
Posted by Michael Wonder on 09 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee (9 November 2023)
9 November 2023 - Two more documents are now available. ...
Posted by Michael Wonder on 08 Nov 2023
PHARMAC publishes agenda for November 2023 PTAC meeting
8 November 2023 - Another underwhelming agenda; yet again there is no application for a cancer medicine. ...
Posted by Michael Wonder on 07 Nov 2023
NICE launches refreshed support service for life sciences industry
6 November 2023 - NICE has today launched its refreshed support service for the life sciences sector, NICE Advice. ...
Posted by Michael Wonder on 04 Nov 2023
Elexacaftor with tezacaftor and ivacaftor, tezacaftor with ivacaftor and lumacaftor with ivacaftor for the treatment of patients with cystic fibrosis
3 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 04 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee (3 November 2023)
3 November 2023 - Further documents from the review are now available. ...
Posted by Michael Wonder on 02 Nov 2023
Rhythm Pharmaceuticals receives positive CADTH reimbursement recommendation for Imcivree (setmelanotide)
2 November 2023 - Recommendation based on demonstrated clinical benefit in Phase 3 trial. ...
Posted by Michael Wonder on 02 Nov 2023
Ivosidenib for the treatment of patients with advanced IDH1 mutation positive cholangiocarcinoma after at least one line of treatment
2 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Nov 2023
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
1 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Nov 2023
Empagliflozin for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction
1 November 2023 - NICE has published final evidence-based recommendations on the use of empagliflozin (Jardiance) for the treatment of ...
Posted by Michael Wonder on 01 Nov 2023
Cabozantinib maleate for previously treated adults with advanced differentiated thyroid cancer that is unsuitable for or refractory to radioactive iodine
1 November 2023 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) for previously treated ...
Posted by Michael Wonder on 31 Oct 2023
NICE launches first modular update to its methods and processes
31 October 2023 - NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of ...
Posted by Michael Wonder on 30 Oct 2023
Updates to the HTA Review Research and analysis papers collection: draft HTA expert paper published (30 October 2023)
30 October 2023 - The draft paper International Health Technology Market Approval, Funding and Assessment Pathways developed to support the ...